Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3144840 | 0.95 | CHEK1 (0.37) | CHEK1GAATLR8TLR7TLR9 | |
| SCHEMBL1360466 | 0.95 | CHEK1 (0.37) | CHEK1GAATLR8TLR7TLR9 | |
| SCHEMBL1358340 | 0.93 | GAA (0.38) | GAAAKR1C3CYP3A4MAPTPARP1 | |
| SCHEMBL12138497 | 0.93 | GAA (0.36) | CHEK1GAAAKR1C3CYP3A4MAPT | |
| SCHEMBL1357909 | 0.90 | KDM1A (0.39) | CHEK1GAATLR8TLR7TLR9 | |
| SCHEMBL1357912 | 0.90 | KDM1A (0.39) | CHEK1GAATLR8TLR7TLR9 | |
| SCHEMBL1359812 | 0.90 | KDM1A (0.39) | CHEK1GAATLR8TLR7TLR9 | |
| SCHEMBL1359264 | 0.89 | CYP3A4 (0.34) | GAAAKR1C3CYP3A4MAPTALDH1A1 | |
| SCHEMBL1359797 | 0.89 | CHEK1 (0.38) | CHEK1GAACYP3A4 | |
| SCHEMBL1359379 | 0.88 | RAB9A (0.39) | GAAPARP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | claimed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | CHEK1 1363/4885GAA 2017/4885TLR8 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.